Drug rediscovery in gastroenterology: From off-label to on-label use of thioguanine in inflammatory bowel disease
De Boer NK, Simsek M, Meijer B, Neurath M, Van Bodegraven A, Mulder CJ (2023)
Publication Type: Journal article, Review article
Publication year: 2023
Journal
Article Number: gutjnl-2023-329679
DOI: 10.1136/gutjnl-2023-329679
Abstract
Drug rediscovery refers to the principle of using € old' drugs outside the indications mentioned in the summary of product characteristics. In the past decades, several drugs were rediscovered in a wide variety of medical fields. One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands. In this paper, we aim to visualise potential hurdles that hamper drug rediscovery in general, emphasise the global need for optimal use and development of potentially useful drugs, and provide an overview of the registration process for TG in the Netherlands. With this summary, we aim to guide drug rediscovery trajectories in the near future.
Authors with CRIS profile
Involved external institutions
Netherlands (NL)How to cite
APA:
De Boer, N.K., Simsek, M., Meijer, B., Neurath, M., Van Bodegraven, A., & Mulder, C.J. (2023). Drug rediscovery in gastroenterology: From off-label to on-label use of thioguanine in inflammatory bowel disease. Gut. https://doi.org/10.1136/gutjnl-2023-329679
MLA:
De Boer, Nanne K.H., et al. "Drug rediscovery in gastroenterology: From off-label to on-label use of thioguanine in inflammatory bowel disease." Gut (2023).
BibTeX: Download